National Cancer Institute support for targeted alpha-emitter therapy

• Published in: European journal of nuclear medicine and molecular imaging 2021-12, Vol.49 (1), p.64-72
• Main Authors: Hong, Julie A., Brechbiel, Martin, Buchsbaum, Jeff, Canaria, Christie A., Coleman, C. Norman, Escorcia, Freddy E., Espey, Michael, Kunos, Charles, Lin, Frank, Narayanan, Deepa, Capala, Jacek
• Format: Article
• Language: English
• Subjects: Cancer; Cancer therapies; Cardiology; Clinical trials; Dosimeters; Dosimetry; Emitters; Humans; Imaging; Interest groups; Medical imaging; Medicine; Medicine & Public Health; National Cancer Institute (U.S.); Neoplasms - radiotherapy; Nuclear Medicine; Oncology; Original Article; Orthopedics; Pharmaceuticals; Quality assurance; R&D; Radiochemistry; Radioisotopes; Radiology; Radiometry; Radiopharmaceuticals; Radiopharmacy; Research & development; Small business; Therapy; United States; Workshops
• ISSN: 1619-7070; 1619-7089; 1619-7089
• DOI: 10.1007/s00259-021-05503-z

Background Radiopharmaceutical targeted therapy (RPT) has been studied for decades; however, recent clinical trials demonstrating efficacy have helped renewed interest in the modality. Methods This article reviews National Cancer Institute (NCI)’s support of RPT through communication via workshops and interest groups, through funding extramural programs in academia and small business, and through intramural research, including preclinical and clinical studies. Results NCI has co-organized workshops and organized interest groups on RPT and RPT dosimetry to encourage the community and facilitate rigorous preclinical and clinical studies. NCI has been supporting RPT research through various mechanisms. Research has been funded through peer-reviewed NCI Research and Program Grants (RPG) and NCI Small Business Innovation Research (SBIR) Development Center, which funds small business-initiated projects, some of which have led to clinical trials. The NCI Cancer Therapy Evaluation Program (CTEP)’s Radiopharmaceutical Development Initiative supports RPT in NCI-funded clinical trials, including Imaging and Radiation Oncology Core (IROC) expertise in imaging QA and dosimetry procedures. Preclinical targeted a-emitter therapy (TAT) research at the NCI’s intramural program is ongoing, building on foundational work dating back to the 1980s. Ongoing “bench-to-bedside” efforts leverage the unique infrastructure of the National Institutes of Health’s (NIH) Clinical Center. Conclusion Given the great potential of RPT, our goal is to continue to encourage its development that will generate the high-quality evidence needed to bring this multidisciplinary treatment to patients.